thrombosis

TCT 2018 | ReCre8 trial: Zotarolimus y polímero permanente vs Amphilimus libre de polímero

TCT 2018 | ReCre8 Trial: Permanent Polymer and Zotarolimus vs. Polymer-Free Amphilimus

Polymer-free amphilimus-eluting stents are a novel technology combining sirolimus and long-chained fatty acids. This enhances the uptake of antiproliferative agents and may be associated with lower restenosis, particularly among patients with diabetes. The new device includes abluminal reservoirs filled with the drug; in consequence, there is no need for polymer. This work compares this new<a href="https://solaci.org/en/2018/10/08/tct-2018-recre8-trial-permanent-polymer-and-zotarolimus-vs-polymer-free-amphilimus/" title="Read more" >...</a>

BIONYX: DES de polímero permanente vs DES ultrafino y polímero bioabsorbible

TCT 2018 | BIONYX: Durable Polymer-Coated vs. Ultrathin-Strut, Bioresorbable Polymer-Coated DES

This work, presented at TCT 2018 and published simultaneously in The Lancet, is the first randomized study comparing a zotarolimus-eluting stent with a new thin-strut structure and limited radiographic visibility (Onyx), and a bioresorbable polymer-coated sirolimus-eluting stent (Orsiro). Onyx was developed to improve visibility while reducing strut thickness. To that end, a dense platinum–iridium core and<a href="https://solaci.org/en/2018/10/08/tct-2018-bionyx-durable-polymer-coated-vs-ultrathin-strut-bioresorbable-polymer-coated-des/" title="Read more" >...</a>

TCT 2018 | RESET: DES liberadores de everolimus vs sirolimus de primera generación a largo plazo

TCT 2018 | RESET: Everolimus DES vs. Sirolimus First Generation DES at Long Term

This study had published thrombosis and revascularization rates at one year after stenting, but today one year seems rather short, which is why this cohort was followed up for 5 to 7 years more, to be able to properly assess the differences between first and second generation DES. There were no significant differences a t<a href="https://solaci.org/en/2018/10/05/tct-2018-reset-everolimus-des-vs-sirolimus-first-generation-des-at-long-term/" title="Read more" >...</a>

TCT 2018 | ULTIMATE: Implante de DES guiado por IVUS, para todos los vasos, para todas las lesiones

TCT 2018 | ULTIMATE: IVUS Guided DES Implantation for All Vessels, for All Lesions

Intravascular Ultrasound (IVUS) guided drug eluting stent (DES) implantation is associated with less adverse events compared against angiography guided stenting. This is especially clear for certain populations (with left main PCI as paradigmatic) but not so clear when dealing with all comers. 1448 all comer patients requiring DES stenting were randomized 1:1 to IVUS guided<a href="https://solaci.org/en/2018/10/05/tct-2018-ultimate-ivus-guided-des-implantation-for-all-vessels-for-all-lesions/" title="Read more" >...</a>

TCT 2018 | PREPARE-CALC: aterectomía rotacional vs Cutting Balloon en lesiones calcificadas

TCT 2018 | PREPARE-CALC: Rotational Atherectomy vs. Cutting Balloon in Calcified Lesions

Compared against conventional predilation with balloon, rotational atherectomy is associated with higher procedural success rate in severely classified lesions. Balloons capable of modifying plaque such as the Flextome Cutting Balloon or the AngioSculpt Scoring Balloon -among others- could reach similar results to that of rotational atherectomy, though this has not been tested so far. 200<a href="https://solaci.org/en/2018/10/05/tct-2018-prepare-calc-rotational-atherectomy-vs-cutting-balloon-in-calcified-lesions/" title="Read more" >...</a>

TCT 2018 | SORT OUT IX: Stent libre de polímero y struts ultrafinos vs polímero bio absorbible

TCT 2018 | SORT OUT IX: Polymer-Free DES with Ultra-Thin Struts vs. Bioresorbable Polymer- Based DES

Polymer persistence in 1st and 2nd generation DES meant to allow drug release has been associated with a chronic inflammatory response that might be associated to restenosis, neo atherosclerosis and stent thrombosis. This is the rationale behind the development of polymer free and bioresorbable polymer-based DES. They have both been compared against permanent polymer DES,<a href="https://solaci.org/en/2018/10/03/tct-2018-sort-out-ix-polymer-free-des-with-ultra-thin-struts-vs-bioresorbable-polymer-based-des/" title="Read more" >...</a>

imperial-TCT 2018

TCT 2018 | IMPERIAL: First Study Comparing Drug-Eluting Stents in Patients with Femoropopliteal Disease

The IMPERIAL trial compared the safety and efficacy of a nitinol self-expanding polymer-free placlitaxel-eluting stent (Zilver PTX, Cook Medical, already approved by the US Food and Drug Administration [FDA]) and a nitinol self-expanding polymer-coating placlitaxel-eluting stent (Eluvia, Boston Scientific). This was a single-blind randomized trial in patients with symptomatic intermittent claudication (Rutherford categories 2, 3, or<a href="https://solaci.org/en/2018/10/03/tct-2018-imperial-first-study-comparing-drug-eluting-stents-in-patients-with-femoropopliteal-disease/" title="Read more" >...</a>

HIV and Peripheral Artery Disease: Acknowledging the Association

The role of human immunodeficiency virus (HIV) in the development of vascular disease (specifically peripheral artery disease) remains unclear. Is the virus per se the direct cause of this disease or is it a consequence of dyslipidemia, one of the adverse effects of antiretrovirals? This study looked into the effect of HIV infection on peripheral<a href="https://solaci.org/en/2018/09/10/hiv-and-peripheral-artery-disease-acknowledging-the-association/" title="Read more" >...</a>

doble antiagregacion plaquetaria sexo

Antiaggregation Time after Treating Bifurcations

Defining dual antiplatelet therapy (DAPT) seems a never-ending story. We go from trials showing the safety of shorter schemes thanks to new generation stents to others suggesting up to two years of DAPT. Rather than finding a general scheme, it seems to be about adjusting DAPT on a case by case basis, according to ischemia<a href="https://solaci.org/en/2018/09/06/antiaggregation-time-after-treating-bifurcations/" title="Read more" >...</a>

GLOBAL LEADERS: El ticagrelor como monoterapia no supera a los esquemas clásicos post angioplastia

ESC 2018 | GLOBAL LEADERS: Ticagrelor Monotherapy Is Not Superior to Classic Therapies After Angioplasty

Dropping aspirin after the first month and continuing with ticagrelor monotherapy was not better than standard dual antiplatelet therapy (aspirin plus ticagrelor or clopidogrel) in patients who underwent coronary angioplasty. Patrick Serruys presented this work (which was simultaneously published in The Lancet) at the European Society of Cardiology (ESC) Congress 2018 and explained that, given<a href="https://solaci.org/en/2018/08/30/esc-2018-global-leaders-ticagrelor-monotherapy-is-not-superior-to-classic-therapies-after-angioplasty/" title="Read more" >...</a>

Top